Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Feb 23.
doi: 10.1002/mds.70236. Online ahead of print.

Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study

Nikolaos Papagiannakis  1 , Christos Koros  1 , Athina-Maria Simitsi  1 , Leonidas Stefanis  1 ; and The Parkinson's Progression Markers Initiative
Collaborators, Affiliations

Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study

Nikolaos Papagiannakis et al. Mov Disord. .

Abstract

Background: Serum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson's disease (iPD) have been inconsistent. The p.A53T SNCA mutation usually leads to a severe form of PD.

Objective: The aim of this work was to assess the possible use of serum NfL as a marker of ongoing neurodegeneration in A53T-PD.

Methods: Using a propensity score matching-based technique with data from the Parkinson's Progression Markers Initiative, we matched, in a 3:1 ratio, A53T-PD participants to iPD patients and healthy control subjects (HCs) by age and disease duration, where applicable.

Results: After matching, 18 A53T-PD, 54 iPD, and 54 HC subjects were analyzed. Serum NfL was higher in A53T-PD (9.82 [8.02-18.1] pg/ml) compared with HCs (7.54 [5.76-10.1], P = 0.008) or iPD patients (8.59 [6.86-11.1], P = 0.077) (overall P = 0.049).

Conclusions: A53T-PD patients have high NfL levels, which could potentially be used as an outcome in clinical trials with disease-modifying agents. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; neurofilament.

PubMed Disclaimer

References

    1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha‐synuclein in Lewy bodies. Nature 1997;388(6645):839–840. https://doi.org/10.1038/42166
    1. Papadimitriou D, Antonelou R, Miligkos M, et al. Motor and nonmotor features of carriers of the p.A53T alpha‐synuclein mutation: a longitudinal study. Mov Disord 2016;31(8):1226–1230. https://doi.org/10.1002/mds.26615
    1. Simitsi AM, Sfikas E, Koros C, et al. Motor and nonmotor features of p.A53T alpha‐synuclein PD vs idiopathic PD: longitudinal data from the PPMI study. J Neurol 2025;272(3):203. https://doi.org/10.1007/s00415-024-12836-w
    1. Bridel C, Van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta‐analysis. JAMA Neurol 2019;76(9):1035. https://doi.org/10.1001/jamaneurol.2019.1534
    1. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90(8):870–881. https://doi.org/10.1136/jnnp-2018-320106

LinkOut - more resources